Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Обзорная статья

The <scp>microRNAs</scp> ( <scp>miRs</scp> ) overexpressing mesenchymal stem cells ( <scp>MSCs</scp> ) therapy in neurological disorders; hope or hype

Sulieman Ibraheem Shelash Al‐HawaryDepartment of Business Administration, Business School Al al‐Bayt University Mafraq JordanAnas Yahya AliDepartment of Nursing Al‐maarif University College Ramadi Al‐Anbar IraqYasser Fakri MustafaDepartment of Pharmaceutical Chemistry, College of Pharmacy University of Mosul Mosul IraqRia MargianaAndrology Program, Faculty of Medicine Universitas Airlangga Surabaya IndonesiaShamsutdinova Maksuda IlyasovnaTashkent Medical Academy Tashkent UzbekistanMontather F. RamadanCollege of Dentistry Al‐Ayen University Thi‐Qar IraqSami G. AlmalkiDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences Majmaah University Majmaah Saudi ArabiaMarim AlwaveMedical Technical College Al‐Farahidi University Baghdad IraqSafa AlkhayyatCollege of Pharmacy The Islamic University Najaf IraqAli AlsalamyCollege of Technical Engineering Imam Ja'afar Al‐Sadiq University Al‐Muthanna Iraq
Biotechnology Progressjournal2023en
ABI

Аннотация

Altered expression of multiple miRNAs was found to be extensively involved in the pathogenesis of different neurological disorders including Alzheimer's disease, Parkinson's disease, stroke, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington's disease. One of the biggest concerns within gene-based therapy is the delivery of the therapeutic microRNAs to the intended place, which is obligated to surpass the biological barriers without undergoing degradation in the bloodstream or renal excretion. Hence, the delivery of modified and unmodified miRNA molecules using excellent vehicles is required. In this light, mesenchymal stem cells (MSCs) have attracted increasing attention. The MSCs can be genetically modified to express or overexpress a particular microRNA aimed with promote neurogenesis and neuroprotection. The current review has focused on the therapeutic capabilities of microRNAs-overexpressing MSCs to ameliorate functional deficits in neurological conditions.

Перевод пока недоступен

Темы

Идентификаторы

Цитирования и источники